CBE ID
0210
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Geriatrics and Palliative Care Spring 2026
1.3 Measure Description
Percentage of patients who died from cancer receiving systemic cancer-directed therapy in the last 14 days of life
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.20 Testing Data Sources
-
1.14 Numerator
Patients who received systemic cancer-directed therapy in the last 14 days of life.
Definitions:
Systemic Cancer-Directed Therapy includes
- All traditional cytotoxic chemotherapy (such as alkylating agents, antimetabolites, plant alkaloids and terpenoids, topoisomerase inhibitors, and antitumor antibiotics);
- Immunotherapy;
- Biologics (such as Herceptin, Rituxan); and
- Targeted agents
Do not include supportive care therapies (e.g., growth factors, bisphosphonates, RANK ligand inhibitors, nausea medications or fluids if these are not given in association with “systemic cancer-directed therapy”). Hormonal therapies and steroids are not included in this systemic cancer directed therapy definition.
-
1.15 Denominator
Patients who died from cancer.
-
Exclusions
None
-
1.13a Data dictionary not attachedNo
-
Most Recent Endorsement ActivityEndorsed Geriatric and Palliative Care Spring 2022Initial EndorsementLast Updated
-
StewardAmerican Society of Clinical OncologySteward Organization POC EmailSteward Organization Copyright
Copyright © 2012-2016 American Society of Clinical Oncology. All right reserved.
-
-
-
Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
-
-
-
6.1.2 Current or Planned Use(s)
-
Planned Use
-